State Pharmaceuticals Corporation Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: State Pharmaceuticals Corporation Pharmaceutical Import Records from India — 14 Products, $4.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

State Pharmaceuticals Corporation — Pharmaceutical Importer Profile (2026) | 14 Products, $4.2M Trade | TransData Nexus

State Pharmaceuticals Corporation

Pharmaceutical Importer · Sri Lanka · Other Focus · $4.2M Total Trade · DGFT Verified

State Pharmaceuticals Corporation is a pharmaceutical importer based in Sri Lanka with a total trade value of $4.2M across 14 products in 8 therapeutic categories. Based on 86 verified import shipments from Indian Customs (DGFT) records, State Pharmaceuticals Corporation is the #1 buyer in 2 products including Immunoglobulin, Morphine. State Pharmaceuticals Corporation sources from 111 verified Indian suppliers, with Alvita Pharma Private Limited accounting for 8.4% of imports.

State Pharmaceuticals Corporation — Import Portfolio & Supplier Network

State Pharmaceuticals Corporation import network — 14 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to State Pharmaceuticals Corporation?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Alvita Pharma Private Limited	$1.9M	69	8.4%
Reliance Life Sciences Private Limited	$1.8M	52	7.7%
Venor Pharma Limited

What Formulations Does State Pharmaceuticals Corporation Import?

Formulation	Value	Ships
Human normal immunoglobulin for	$450.0K	9
Diagnostic kits meriscreen dengue ns1	$350.0K	7
Raksharab 10 ML(veterinary rabies	$300.0K	6
Pharmaceutical finished formulation clindabact-150 (clindamycin injection BP 150MG/ML), 10 x 2 ML ampoules,e, sri	$290.5K	16
Pharmaceutical products glytad	$250.0K	5
Nicardia retard 20MG 5x10t srl exp -	$243.0K	5
Acecloright (aceclofenac tablets 100MG	$218.2K	9
Elastic adhesive bandage b.p. 1993	$209.2K	6
Morphine sulphate INJ BP 2MG/2ML	$200.0K	4
Clopid (clopidogrel tablets USP 75 MG )	$200.0K	4
Clopid (clopidogrel tablets USP 75 MG)	$200.0K	4
63619 packs of gliclazide modified	$200.0K	4
Phenylephrine INJ BP 10MG/ML,1ML	$194.5K	4
Pantoprazole sodium delayed release tablets USP 40MG	$182.7K	7
Prazoright (prazosin tablets BP 1MG	$150.9K	5

State Pharmaceuticals Corporation imports 557 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 14 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Immunoglobulin	Other	$850.0K	17	0.5%	1
2	Heparin	Cardiovascular	$500.0K	10	0.1%	14
3	Enoxaparin	Cardiovascular	$400.0K	8	0.2%	9
4	Morphine	Analgesics & Antipyretics	$400.0K	8	2.2%	1
5	Sitagliptin	Diabetes & Endocrine	$400.0K	8	0.5%	8
6	Rituximab	Advanced Oncology	$300.0K	6	1.6%	2
7	Syringe	Medical Devices & Diagnostics	$300.0K	6	0.2%	12
8	Domperidone	Gastrointestinal	$200.0K	4	0.7%	15
9	Serum	Other	$200.0K	4	0.7%	14
10	Pazopanib	Advanced Oncology	$156.6K	4	1.9%	5
11	Fentanyl	Analgesics & Antipyretics	$150.0K	3	4.0%	2
12	Lactulose	Gastrointestinal	$150.0K	3	1.1%	8
13	Cyclosporine	Immunosuppressants	$125.9K	3	1.0%	11
14	Sulfasalazine	Gastrointestinal	$96.6K	2	3.0%	9

State Pharmaceuticals Corporation imports 14 pharmaceutical products across 8 categories into Sri Lanka totaling $4.2M. The company is the #1 buyer for 2 products: Immunoglobulin, Morphine.

State Pharmaceuticals Corporation — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The State Pharmaceuticals Corporation (SPC) is a state-owned enterprise headquartered in Colombo, Sri Lanka. Established in 1971 under the State Industrial Corporations Act Number 49 of 1957, SPC was founded following the recommendations of the Bibile-Wickramasinghe Commission, which aimed to ensure the availability of quality-assured pharmaceuticals at affordable prices. The corporation is dedicated to providing safe and effective healthcare products, including pharmaceuticals, surgical consumables, laboratory chemicals, and equipment, to both public and private sectors. SPC operates a network of Rajya Osusala pharmacies and franchise outlets across the country, ensuring widespread access to essential medications. The corporation employs approximately 600 staff members and plays a pivotal role in promoting the rational use of drugs among the Sri Lankan population. (spc.lk)

2Distribution Network

SPC's distribution network is extensive, encompassing 18 Rajya Osusala pharmacies, 36 franchise outlets, 48 distributors, and 20 authorized retailers throughout Sri Lanka. This widespread presence ensures that essential medications are accessible to communities nationwide. The corporation's logistics capabilities are robust, facilitating the efficient procurement and distribution of pharmaceuticals to meet the demands of both the public and private healthcare sectors. While the primary focus is on domestic distribution, SPC's operations also support the export of locally manufactured medicines, contributing to the global pharmaceutical supply chain. (spc.lk)

3Industry Role

SPC serves as the primary wholesaler and distributor of pharmaceuticals in Sri Lanka, supplying a wide range of medications to both public and private healthcare institutions. As the sole supplier to all institutions administered by the Ministry of Health, SPC plays a critical role in ensuring the availability of essential medicines across the country. Additionally, the corporation's network of Rajya Osusala pharmacies and franchise outlets positions it as a key player in the retail distribution of pharmaceuticals, making it a central figure in Sri Lanka's pharmaceutical supply chain. (spc.lk)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — State Pharmaceuticals Corporation

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

SPC's sourcing strategy demonstrates a significant concentration on a select group of Indian suppliers. The top five suppliers—ALVITA PHARMA PRIVATE LIMITED, RELIANCE LIFE SCIENCES PRIVATE LIMITED, VENOR PHARMA LIMITED, USV PRIVATE LIMITED, and WALLACE PHARMACEUTICALS PRIVATE LIMITED—collectively account for approximately 69% of SPC's total import value from India. This concentration indicates a strategic choice to maintain stable and reliable relationships with key suppliers, potentially ensuring consistent quality and supply. However, such dependency also poses risks; any disruptions with these suppliers could significantly impact SPC's ability to meet domestic pharmaceutical demands. The shipment data, with 86 total shipments across 14 products, suggests a diversified product portfolio, which may help mitigate some risks associated with supplier concentration.

2Supply Chain Resilience

SPC's supply chain resilience is closely tied to its relationships with Indian suppliers. The corporation's focus on a limited number of suppliers for a substantial portion of its imports indicates a strategic approach to ensure quality and reliability. However, this concentration also means that any disruptions—such as production issues, regulatory changes, or logistical challenges—could have a significant impact on SPC's ability to supply essential medications domestically. The diversity of formulations imported, spanning eight therapeutic categories, provides some buffer against supply chain disruptions, as it allows SPC to source alternative products from different suppliers if necessary. Nonetheless, the heavy reliance on a few key suppliers underscores the importance of maintaining strong, resilient relationships and having contingency plans in place to address potential supply chain challenges.

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing the pharmaceutical sector in Sri Lanka. Established in 2015 through the National Medicines Regulatory Authority Act, No. 5 of 2015, the NMRA is responsible for ensuring the safety, efficacy, and quality of medicines, medical devices, and related products within the country. The NMRA regulates the manufacturing, importation, distribution, and sale of medicines, as well as clinical trials conducted in Sri Lanka. This regulatory framework is designed to protect public health by ensuring that all medicinal products meet applicable standards. (nmra.gov.lk)

2Import Licensing & GMP

Import licensing in Sri Lanka is governed by the NMRA, which ensures that all imported medicines comply with the country's regulatory standards. Manufacturers and suppliers must obtain the necessary approvals from the NMRA before exporting pharmaceutical products to Sri Lanka. Good Manufacturing Practice (GMP) certification is a critical requirement for pharmaceutical imports. The NMRA recognizes GMP certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Suppliers seeking to export to Sri Lanka must ensure that their manufacturing facilities are GMP-compliant and that their products meet the quality standards set by the NMRA.

State Pharmaceuticals Corporation — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

SPC's product strategy focuses on a diverse range of therapeutic categories, with significant imports in areas such as immunology, cardiovascular, and analgesics & antipyretics. The corporation's top five imported products—Immunoglobulin, Heparin, Enoxaparin, Morphine, and Sitagliptin—reflect a strategic emphasis on critical and high-demand medications. The substantial import value in these categories indicates a strong market demand and SPC's commitment to ensuring the availability of essential treatments for the Sri Lankan population. The corporation's focus on generic drugs aligns with its mission to provide affordable healthcare solutions while maintaining high-quality standards.

2Sourcing Profile

SPC's sourcing strategy is heavily concentrated on Indian suppliers, with the top five suppliers accounting for approximately 69% of the total import value. This concentration suggests a strategic choice to maintain stable and reliable relationships with key suppliers, potentially ensuring consistent quality and supply. The diversity of formulations imported, spanning eight therapeutic categories, provides some buffer against supply chain disruptions, as it allows SPC to source alternative products from different suppliers if necessary. However, the heavy reliance on a few key suppliers underscores the importance of maintaining strong, resilient relationships and having contingency plans in place to address potential supply chain challenges.

Seller's Guide — How to Become a Supplier to State Pharmaceuticals Corporation

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, there is a realistic opportunity to engage with SPC by meeting the corporation's stringent quality standards and regulatory requirements. While SPC's current sourcing is concentrated on a select group of suppliers, the corporation's diverse product portfolio and ongoing commitment to quality suggest potential openings for additional suppliers, especially those offering unique or high-demand products. Indian exporters can explore these opportunities by ensuring compliance with GMP standards, obtaining necessary certifications, and demonstrating the ability to meet SPC's quality and delivery expectations.

2Requirements & Qualifications

Indian exporters seeking to supply SPC must ensure that their manufacturing facilities are compliant with international GMP standards recognized by the NMRA, such as WHO GMP and PIC/S certifications.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — State Pharmaceuticals Corporation

What products does State Pharmaceuticals Corporation import from India?

State Pharmaceuticals Corporation imports 14 pharmaceutical products across 8 categories. Top imports: Immunoglobulin ($850.0K), Heparin ($500.0K), Enoxaparin ($400.0K), Morphine ($400.0K), Sitagliptin ($400.0K).

Who supplies pharmaceuticals to State Pharmaceuticals Corporation from India?

State Pharmaceuticals Corporation sources from 111 verified Indian suppliers. The primary supplier is Alvita Pharma Private Limited (8.4% of imports, $1.9M).

What is State Pharmaceuticals Corporation's total pharmaceutical import value?

State Pharmaceuticals Corporation's total pharmaceutical import value from India is $4.2M, based on 86 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does State Pharmaceuticals Corporation focus on?

State Pharmaceuticals Corporation imports across 8 categories. The largest: Other (24.8%), Cardiovascular (21.3%), Analgesics & Antipyretics (13.0%).

Get Full State Pharmaceuticals Corporation Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.